产品简要
公司名称 :
ACROBiosystems
产品类型 :
蛋白
产品名称 :
Human S100P / S100E Protein, Tag Free
目录 :
S1P-H5110
规格 :
100微克, 1毫克
价格 :
250美元, 1300美元
更多信息或购买 :
产品信息
公司名称 :
ACROBiosystems
产品类型 :
蛋白
目录 :
S1P-H5110
产品名称 :
Human S100P / S100E Protein, Tag Free
规格 :
100微克, 1毫克
价格 :
250美元, 1300美元
规格&价格 :
$250/100ug,$1300/1mg (500ug × 2)
靶标 :
S100P
宿主物种 :
人类
By Tag :
Tag Free
研究 :
For Research Use Only
来源 :
Human S100P, Tag Free (S1P-H5110) is expressed from E.coli cells. It contains AA Met 1 - Lys 95 (Accession # AAH06819).
内毒素 :
Less than 1.0 EU per μg by the LAL method.
纯度 :
>95% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human S100P, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
配方 :
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH8.0. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
重组 :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
储存 :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
背景 :
S100 calcium-binding protein P (S100P),a member of the S-100 family, is also known as protein S100-P, migration-inducing gene 9 protein (MIG9) and protein S100-E,which contains two EF-hand domains. As for subunit structure,S100P is homodimer and heterodimer with S100A1. S100P may function as calcium sensor and contribute to cellular calcium signaling. In a calcium-dependent manner, S100P functions by interacting with other proteins, such as EZR and PPP5C, and indirectly plays a role in physiological processes like the formation of microvilli in epithelial cells. Furthermore,S100P may stimulate cell proliferation in an autocrine manner via activation of the receptor for activated glycation end products (RAGE).
参考文献 :
(1) Becker T., et al., 1992, Eur. J. Biochem. 207:541-547.
(2) Koltzscher M., et al., 2003, Mol. Biol. Cell 14:2372-2384.
(3) Arumugam T., et al., 2004, J. Biol. Chem. 279:5059-5065.
更多信息或购买 :
公司信息
ACROBiosystems
1 Innovation Way Newark, DE 19711, USA
order@acrobiosystems.com
http://www.acrobiosystems.com1-800-810-0816
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.